


# Stakeholder Communication

Stakeholders	Dialogue Engagement in FY2022
Shareholders and investors	<ul style="list-style-type: none"> <li>IR Meetings with analysts and institutional investors: 78 times; total of 98 participants</li> <li>Financial results presentation and IR events: 3 times; total of 102 participants</li> <li>Briefings for individual investors: 1 time; total of 865 participants</li> <li>General Meeting of Shareholders, attendance at venue: 37 people</li> </ul>
Medical professionals	<ul style="list-style-type: none"> <li>Lectures for medical professionals: 63 times; total of 33,895 participants * Including online participants</li> </ul>
Veterinary medical professionals and farmers	<ul style="list-style-type: none"> <li>Seminars for veterinary medical professionals and farmers: 2 times; total of 700 participants</li> </ul>
Local community	<ul style="list-style-type: none"> <li>Provision of information on female healthcare through Mint+ and Mint+ teens ▶ See page 43 for details.</li> <li>Seminars for general public (patients): 4 times; total of 740 participants</li> </ul>
Employees	<ul style="list-style-type: none"> <li>Dialogue with management: 98 times ▶ See page 38 for details.</li> </ul>

The Group engages with a wide range of stakeholders including shareholders and investors, medical professionals, veterinary medical professionals, farmers, partners, local communities, patients and their families, and employees.

Our corporate communication activities are guided by the basic principles of transparency, fairness, and continuity as we work to deepen mutual understanding with stakeholders and earn the trust of society.

**Investor Relations website (For Our Shareholders and Investors)**  
<https://www.aska-pharma-hd.co.jp/english/invest/>



**Health Lab Mint+ for Women's health (Japanese version only)**  
<https://www.aska-pharma.co.jp/mint/>



## External Evaluation Related to ESG



**FTSE Blossom Japan Index**

FTSE Blossom Japan Index



**FTSE Blossom Japan Sector Relative Index**

FTSE Blossom Japan Sector Relative Index



S&P/JPX Carbon Efficient Index

## Editorial Postscript

Thank you for reading *ASKA HD Report 2023*. In this report, we focused on the distinctive material issues of ASKA Pharmaceutical Holdings, namely contribution to women's health and contribution to animal health, presenting the messages and business strategies of the Group's presidents and division heads. We also outlined the Group's commitment to sustainable corporate value enhancement. This report greatly expanded our coverage of the Group's human resources strategy, which is the

foundation of the Group's growth. We hope that this report has helped you better understand the Group's efforts. We will continue to value opportunities for engaging with our stakeholders as we strive to enhance our information disclosure.

Corporate Communication Section  
 Corporate Planning Department  
 ASKA Pharmaceutical Holdings